XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
January 29 2014 - 8:30AM
Business Wire
XenoPort, Inc. (Nasdaq:XNPT) announced today that Richard Kim,
M.D., has been appointed senior vice president, clinical
development and medical affairs, and chief medical officer. Dr. Kim
joined XenoPort in July 2013 as vice president of medical affairs,
supporting XenoPort’s launch of HORIZANT® (gabapentin enacarbil)
Extended-Release Tablets. Dr. Kim has more than a decade of
experience in both clinical development and medical affairs, most
recently as vice president of clinical development and head of the
multiple sclerosis therapeutic area at Elan Pharmaceuticals,
Inc.
"We are excited to have Richard take an expanded role as we
advance XP23829 into planned Phase 2 development," said Ronald W.
Barrett, Ph.D., chief executive officer of XenoPort. “Richard’s
experience in Phase 1 through 4 clinical development, particularly
in autoimmune diseases such as multiple sclerosis, is a valuable
addition to the XenoPort team.”
In his previous position at Elan, Dr. Kim was joint program team
leader for natalizumab (TYSABRI), which is approved globally for
treatment of multiple sclerosis and approved for treatment of
Crohn’s Disease in the United States. Prior to Elan, he was the
global medical affairs director for natalizumab at Biogen Idec
Inc., during which he played an integral role in successfully
re-launching TYSABRI in the United States, as well as its
subsequent global launch. Prior to Biogen Idec, he was the medical
director responsible for the cladribine Phase 3 program at EMD
Serono, Inc. He began his industry career more than a decade ago at
Purdue Pharma L.P., where he worked on the early development of
buprenorphine transdermal patch (BUTRANS).
Dr. Kim received his medical degree from Tulane University,
completed his neurology residency training at Stanford University,
and is a diplomat of the American Board of Psychiatry and
Neurology.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing HORIZANT in the
United States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for psoriasis and/or
relapsing forms of multiple sclerosis (MS). REGNITE® (gabapentin
enacarbil) Extended-Release Tablets is being marketed in Japan by
Astellas Pharma Inc. XenoPort's pipeline of product candidates also
includes potential treatments for patients with spasticity related
to spinal cord injury and Parkinson's disease. To learn more about
XenoPort, please visit the website at www.XenoPort.com.
Forward-Looking Statements
This press release contains “forward-looking” statements,
including, without limitation, all statements related to the
potential suitability of XP23829 as a treatment for
moderate-to-severe plaque psoriasis and/or relapsing forms of MS,
and advancing XP23829 into planned Phase 2 development. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as “planned,” “potential” and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon XenoPort's current
expectations. Forward-looking statements involve risks and
uncertainties. XenoPort's actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation: risks related to
XenoPort’s ability to successfully advance XP23829 development and
to conduct or initiate clinical trials in the anticipated
timeframes, or at all; the difficulty and uncertainty of
pharmaceutical product development and the uncertain results and
timing of clinical trials and other studies, including the risk
that success in preclinical testing and early clinical trials does
not ensure that later clinical trials will be successful, and that
the results of clinical trials by other parties may not be
indicative of the results in trials that XenoPort may conduct; the
uncertainty of the U.S. Food and Drug Administration’s (FDA’s)
review process and other regulatory requirements; XenoPort's need
for and the availability of resources to develop XenoPort's product
candidates and support XenoPort's operations; and the uncertain
therapeutic and commercial value of XenoPort's product candidates.
These and other risk factors are discussed under the heading "Risk
Factors" in XenoPort’s prospectus supplement, filed with the
Securities and Exchange Commission under Rule 424(b)(5) on January
24, 2014. XenoPort expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in the company's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2G
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024